Jazz Pharmaceuticals plc (J7Z) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) has a cash flow conversion efficiency ratio of 0.120x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€474.62 Million ≈ $554.88 Million USD) by net assets (€3.96 Billion ≈ $4.63 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jazz Pharmaceuticals plc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Jazz Pharmaceuticals plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jazz Pharmaceuticals plc debt and liabilities for a breakdown of total debt and financial obligations.
Jazz Pharmaceuticals plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jazz Pharmaceuticals plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acuity Brands Inc
NYSE:AYI
|
0.050x |
|
Beijing YanDong MicroElectronic Co. Ltd. A
SHG:688172
|
N/A |
|
Zhejiang Dahua Technology Co Ltd
SHE:002236
|
0.024x |
|
ENN ENERGY HLD.UNS.ADR/25
F:XGH0
|
N/A |
|
Sofina Société Anonyme
BR:SOF
|
0.002x |
|
Baxter International Inc
NYSE:BAX
|
0.096x |
|
Itissalat Al-Maghrib
PA:IAM
|
0.538x |
|
Petronas Gas Bhd
KLSE:6033
|
0.064x |
Annual Cash Flow Conversion Efficiency for Jazz Pharmaceuticals plc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Jazz Pharmaceuticals plc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Jazz Pharmaceuticals plc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €4.09 Billion ≈ $4.79 Billion |
€1.40 Billion ≈ $1.63 Billion |
0.341x | +16.69% |
| 2023-12-31 | €3.74 Billion ≈ $4.37 Billion |
€1.09 Billion ≈ $1.28 Billion |
0.292x | -29.11% |
| 2022-12-31 | €3.09 Billion ≈ $3.61 Billion |
€1.27 Billion ≈ $1.49 Billion |
0.412x | +109.95% |
| 2021-12-31 | €3.97 Billion ≈ $4.64 Billion |
€778.51 Million ≈ $910.16 Million |
0.196x | -20.13% |
| 2020-12-31 | €3.66 Billion ≈ $4.28 Billion |
€899.65 Million ≈ $1.05 Billion |
0.246x | -1.50% |
| 2019-12-31 | €3.11 Billion ≈ $3.64 Billion |
€776.40 Million ≈ $907.69 Million |
0.250x | -13.86% |
| 2018-12-31 | €2.76 Billion ≈ $3.22 Billion |
€798.90 Million ≈ $934.00 Million |
0.290x | +13.41% |
| 2017-12-31 | €2.71 Billion ≈ $3.17 Billion |
€693.09 Million ≈ $810.29 Million |
0.255x | -19.04% |
| 2016-12-31 | €1.88 Billion ≈ $2.19 Billion |
€592.39 Million ≈ $692.57 Million |
0.316x | -5.17% |
| 2015-12-31 | €1.60 Billion ≈ $1.87 Billion |
€531.94 Million ≈ $621.90 Million |
0.333x | +11.94% |
| 2014-12-31 | €1.37 Billion ≈ $1.60 Billion |
€407.61 Million ≈ $476.53 Million |
0.297x | +33.52% |
| 2013-12-31 | €1.30 Billion ≈ $1.51 Billion |
€288.43 Million ≈ $337.21 Million |
0.223x | -- |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LG… Read more